AbbVie (ABBV) Q4 2024 Annual Earnings
ABBV·Reported January 31, 2025·Before market open
AbbVie reported Q4 2024 revenue of $15.1B, beat analyst consensus of $14.8B by $270.5M. Diluted EPS came in at $2.16, missed the $2.98 consensus by $0.82. AbbVie reports across 2 business segments, led by Biopharmaceutical Products and Aesthetics.
Revenue
$15.1Bbeat by $270.5M
Consensus: $14.8BDiluted EPS
$2.16missed by $0.82
Consensus: $2.98
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about AbbVie's Q4 2024 earnings report.
AbbVie (ABBV) reported Q4 2024 earnings on January 31, 2025 before market open.
AbbVie reported revenue of $15.1B and diluted EPS of $2.16 for Q4 2024.
Revenue beat the consensus estimate of $14.8B by $270.5M. EPS missed the consensus estimate of $2.98 by $0.82.
You can read the 10-K periodic report (0001551152-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.